Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on systemic therapy for muscle-invasive urothelial bladder cancer, as substantial revisions were made in the 2017 updates, such as new recommendations for nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab. The complete version of the NCCN Guidelines for Bladder Cancer addresses additional aspects of the management of bladder cancer, including non-muscle-invasive urothelial bladder cancer and nonurothelial histologies, as well as staging, evaluation, and follow-up.
Spiess, PE; Agarwal, N; Bangs, R; Boorjian, SA; Buyyounouski, MK; Clark, PE; Downs, TM; Efstathiou, JA; Flaig, TW; Friedlander, T; Greenberg, RE; Guru, KA; Hahn, N; Herr, HW; Hoimes, C; Inman, BA; Jimbo, M; Kader, AK; Lele, SM; Meeks, JJ; Michalski, J; Montgomery, JS; Pagliaro, LC; Pal, SK; Patterson, A; Plimack, ER; Pohar, KS; Porter, MP; Preston, MA; Sexton, WJ; Siefker-Radtke, AO; Sonpavde, G; Tward, J; Wile, G; Dwyer, MA; Gurski, LA
Volume / Issue
Start / End Page
Pubmed Central ID
Electronic International Standard Serial Number (EISSN)
Digital Object Identifier (DOI)